Shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) fell 3.7% during mid-day trading on Monday . The stock traded as low as $14.05 and last traded at $14.41, with a volume of 305,583 shares. The stock had previously closed at $14.96.

Several research firms have issued reports on BLCM. Piper Jaffray Cos. reiterated a “buy” rating on shares of Bellicum Pharmacueticals in a research note on Saturday. Zacks Investment Research upgraded shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday. SunTrust Banks Inc. began coverage on shares of Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Jefferies Group lowered their price objective on shares of Bellicum Pharmacueticals from $35.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, March 15th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $28.00.

The company’s 50-day moving average is $12.76 and its 200-day moving average is $11.45. The firm’s market cap is $375.08 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.07. On average, equities research analysts forecast that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current year.

In other Bellicum Pharmacueticals news, VP Ken Moseley sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total value of $195,000.00. Following the completion of the transaction, the vice president now directly owns 15,196 shares in the company, valued at $197,548. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CTO Kevin M. Slawin sold 55,000 shares of the company’s stock in a transaction that occurred on Friday, April 22nd. The stock was sold at an average price of $11.43, for a total transaction of $628,650.00. Following the completion of the transaction, the chief technology officer now owns 159,206 shares of the company’s stock, valued at $1,819,724.58. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley boosted its position in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned approximately 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent reporting period.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.